Leonardo Viana Nicacio appointed as chief medical officer at Corbus Pharmaceuticals Holdings, Inc.

Leonardo Viana Nicacio appointed as chief medical officer at Corbus Pharmaceuticals Holdings, Inc.
Corbus names new chief medical officer

Corbus Pharmaceuticals Holdings, Inc. has appointed Leonardo Viana Nicacio, M.D., as its new chief medical officer.

Dr. Nicacio joins Corbus Pharmaceuticals Holdings, Inc. with over 20 years of pharmaceutical industry experience, including a key role in bringing TIVDAK to market for metastatic cervical cancer. His leadership is expected to drive the company’s clinical and medical affairs efforts as it advances its therapeutic portfolio. Further details can be accessed through the company’s official channels.

Corbus Pharmaceuticals Holdings, Inc. recently unveiled updated Phase 1/2 data for its CRB-701 program targeting HPV positive oropharyngeal squamous cell carcinoma (OPSSC). The company has outlined a focus on advancing its pipeline in this oncology indication. The appointment of Dr. Nicacio comes as Corbus expands its clinical development efforts.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.